# | Aladdin ID | Assay Type | Description | Organism | Compounds | Reference | BAO Format | Source | |
---|---|---|---|---|---|---|---|---|---|
1. | ALA2328044 | F | Inhibition of LRRK2 G2019S mutant autophosphorylation at ser1292 in ip dosed transgenic mouse assessed as unbound brain concentration | Mus musculus | 1 | organism-based format | Scientific Literature | ||
2. | ALA2328045 | F | Inhibition of LRRK2 G2019S mutant autophosphorylation at ser1292 in ip dosed transgenic mouse brain | Mus musculus | 1 | organism-based format | Scientific Literature | ||
3. | ALA2328046 | B | Inhibition of TSSK1 (unknown origin) at 1 uM | Homo sapiens | 1 | single protein format | Scientific Literature | ||
4. | ALA2328047 | A | Oral bioavailability in beagle dog at 1 mg/kg | Canis lupus familiaris | 1 | organism-based format | Scientific Literature | ||
5. | ALA2328167 | A | Plasma clearance in beagle dog at 0.5 mg/kg, iv and 1 mg/kg, po | Canis lupus familiaris | 1 | organism-based format | Scientific Literature | ||
6. | ALA2328168 | A | Ratio of unbound drug level in brain to plasma in Sprague-Dawley rat at 0.5 mg/kg, iv | Rattus norvegicus | 2 | organism-based format | Scientific Literature | ||
7. | ALA2328169 | A | Volume of distribution in Sprague-Dawley rat at 0.5 mg/kg, iv | Rattus norvegicus | 2 | organism-based format | Scientific Literature | ||
8. | ALA2328170 | A | Plasma clearance in Sprague-Dawley rat at 0.5 mg/kg, iv | Rattus norvegicus | 2 | organism-based format | Scientific Literature | ||
9. | ALA2328171 | A | Time dependent inhibition of CYP1A2 in human liver microsomes using phenacetin as substrate at 10 x IC50 after 30 mins | Homo sapiens | 14 | microsome format | Scientific Literature | ||
10. | ALA2328172 | A | Reversible inhibition of CYP1A2 (unknown origin) using phenacetin as substrate by LC-MS/MS analysis | Homo sapiens | 14 | single protein format | Scientific Literature | ||
11. | ALA2328173 | A | Efflux ratio of apparent permeability across basolateral to apical side to apical to basolateral side in MDCKI cells transfected with human MDR1 gene at 5 uM | Canis lupus familiaris | 14 | cell-based format | Scientific Literature | ||
12. | ALA2328175 | B | Inhibition of LRRK2 (unknown origin) autophosphorylation by cell-based assay | Homo sapiens | 7 | cell-based format | Scientific Literature | ||
13. | ALA2328176 | B | Inhibition of GST-tagged LRRK2 (unknown origin) G2019S mutant after 1 hr by HTRF assay | Homo sapiens | 17 | single protein format | Scientific Literature | ||
14. | ALA2328177 | P | Thermodynamic solubility of the compound at pH 7.4 | 2 | small-molecule physicochemical format | Scientific Literature | |||
15. | ALA3124208 | A | Oral bioavailability in cynomolgus monkey at 1 to 20 mg/kg | Macaca fascicularis | 1 | organism-based format | Scientific Literature | ||
16. | ALA3124209 | A | Drug metabolism in human hepatocytes assessed as glucuronidated parent compound level after 3 hrs | Homo sapiens | 2 | cell-based format | Scientific Literature | ||
17. | ALA3124217 | B | Selectivity ratio of Ki for JAK2 (unknown origin) to Ki for LRRK2 (unknown origin) | Homo sapiens | 20 | assay format | Scientific Literature | ||
18. | ALA4018177 | A | Inhibition of full length wild-type LRRK2 (unknown origin) using biotinylated ezrin/radaxin/meosin peptide as substrate measured after 1 hr | Homo sapiens | 14 | single protein format | Scientific Literature |